Telix Manufacturing Solutions (TMS) Established in Yokohama, Japan
News,
Read moreNews & Views
Telix Highlights ProstACT Global, CUPID and STARLITE Therapy Studies in Prostate and Kidney Cancer at ASCO Annual Meeting 2025
News,
Read more
Telix Responds to Recent U.S. Government Actions- Most Favored Nation
News,
Telix advises that it has evaluated the Executive Order issued by the United States (U.S.) Government to implement a “Most-Favored Nation” (MFN) policy around drug pricing. Based on currently available…
Read more
Illuccix China Phase 3 Study Completes Enrolment
Telix today announces that that the pivotal Phase 3 registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11) for prostate cancer imaging in Chinese patients has completed patient…
Read more
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy
News,
Telix today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been published in Thyroid, the official journal of the American Thyroid Association. The candidate demonstrated an encouraging…
Read moreTelix’s Illuccix® PSMA-PET Imaging Agent Approved in the Czech Republic
News,
Telix today announces that its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in the Czech Republic by the…
Read more
Illuccix Prostate Cancer PSMA-PET Imaging Agent Approved in Finland
News,
Telix announces its Annual General Meeting of shareholders to be held…
Read more
Telix’s Illuccix PSMA-PET Imaging Agent Approved in France
Telix announces its Annual General Meeting of shareholders to be held…
Read more